


Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:

<http://www.elsevier.com/copyright>



Contents lists available at ScienceDirect

Journal of Fluorine Chemistry

journal homepage: www.elsevier.com/locate/fluor

Polyfluoroalkylated tripyrazolymethane ligands: Synthesis and complexes

Veronika Skalická^a, Markéta Rybáčková^a, Martin Skalický^a, Magdalena Kvíčalová^b, Josef Cvačka^c, Anna Březinová^c, Jan Čejka^d, Jaroslav Kvíčala^{a,*}^a Department of Organic Chemistry, Institute of Chemical Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic^b Institute of Inorganic Chemistry, Academy of Sciences of the Czech Republic, v.v.i., Husinec-Řež 1001, 250 68 Řež, Czech Republic^c Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, v.v.i., Flemingovo nám. 2, 166 10 Prague 6, Czech Republic^d Department of Solid State Chemistry, Institute of Chemical Technology, Prague, Technická 5, 166 28 Prague 6, Czech Republic

ARTICLE INFO

Article history:

Received 5 January 2011

Received in revised form 12 April 2011

Accepted 14 April 2011

Available online 22 April 2011

Keywords:

Tripyrazolymethane

Tp_m

Tripyrazolyethanol

Fluorinated

Perfluoroalkylation

Ligand

Sandwich complex

ABSTRACT

Tripyrazolymethanes represent a novel class of uncharged ligands analogous to charged tripyrazolylborates (scorpionates), which are isoelectronic and isolobal with cyclopentadienides. We report here a straightforward synthesis of the first polyfluoroalkylated tripyrazolymethane ligands bearing C₄F₉–C₁₂F₂₅ ponytails, based on allylation/perfluoroalkylation/reduction sequence of transformations of 2,2,2-tripyrzazol-1-ylethanol. Model complexation reactions of these ligands gave sandwich complexes of copper(II), nickel(II), cobalt(II) and iron(II), the structure of which was confirmed by detailed MS analysis, as well as by NMR spectroscopy for the fourth diamagnetic complex. Fluorophilicity of the ligands and their complexes peaks for C₁₀F₂₁ ponytail but lies below zero.

© 2011 Elsevier B.V. All rights reserved.

1. Introduction

Both heavy and light fluororous chemistry, albeit still a newcomer in the field of organic and organometallic chemistry, had already established a distinguished place in science [1]. Among numerous applications, robust fluororous ligands allowing recycle of often highly valued and expensive homogeneous catalysts still remain a formidable challenge for organofluorine chemists. Due to simple preparation and substantial variability, polyfluorinated phosphane-based ligands still represent a major class of fluororous ligands despite their low oxidation stability limiting their recycle [2].

Surprisingly little attention has been paid to the synthesis of fluororous cyclopentadienes and cyclopentadienide sandwich complexes derived from them, especially having in mind broad impact and wide industrial use of their non-fluorinated counterparts. Nevertheless, several classes of light fluororous cyclopentadienes and cyclopentadienides are known differing mainly in the character of the polyfluorinated ponytail and the length of the non-fluorinated spacer separating it from the core. Thus, ligands and complexes with the fluoroalkyl chains with no spacer [3],


methylene [4], ethylene [5], or trimethylene [6] spacer, as well as with fluorosilyl chains [7] have been synthesized.

On the other hand, a number of heavy fluororous cyclopentadienes and cyclopentadienides known, which generally require multiple polyfluorinated chains attached, is highly limited [8], the main problem in their synthesis being the regioselectivity issue [8b,8c]. Moreover, multiple polyfluoroalkylation severely limits their complexation ability, probably due to excessive steric hindrance of polyfluorinated ponytails [8f]. This prompted our search for cyclopentadienide analogues allowing both selective multiple regioselective polyfluoroalkylation and facile complexation of multiply polyfluoroalkylated ligands.

Tripyrazolylborates (also nicknamed scorpionates due to their ability of optional two- or threefold coordination in analogy to a scorpion biting its prey with two claws and optionally with a tail) represent a comparably novel class of wide scope ligands with a three-dimensional character [9] (in contrast to the two-dimensional cyclopentadienides), isoelectronic and isolobal with the cyclopentadienides. Scorpionates can be modified with a high level of regioselectivity [10], however, their anionic borate core does not allow purification by column chromatography. In contrast to that, analogous tripyrazolymethane ligands retain high proneness to regioselective functionalization while being much more easily purifiable [11] and thus logically attracted our attention as the first candidate for the cyclopentadiene substitute. In this paper we

* Corresponding author.

E-mail address: kvicalaj@vscht.cz (J. Kvíčala).



Scheme 1.

wish to report our approach to the polyfluoroalkylated tripyrazolymethanes based on the modification of the methine carbon of the tripyrazolymethane core.

2. Results and discussion

2.1. Synthesis of the ligands

In contrast to the two-dimensional cyclopentadienide anions containing five identical carbons, tripyrazolymethanes offer in principle four different positions for selective modifications, viz. C3, C4 and C5 carbons of the pyrazole rings, and the methine carbon connecting the three heteroaromatic rings. The simplest way how to modify the methine carbon consists of lithiation followed by attack on an electrophile [12]. Due to the inferior reactivity of polyfluoroalkylated electrophiles [8a] and potential problems with complexations caused by steric hindrance of the methine-substituted tripyrazolymethanes [13], we decided to modify the parent skeleton first with a hydroxymethyl group according to the original Reger's paper [14] and obtained the key intermediate, 2,2,2-tripyrazol-1-ylethanol (**1**), in an acceptable yield.

To obtain the ligands with as high fluorophilicity as possible we attempted to keep the non-fluorinated spacer between the perfluoroalkyl chain and the tripyrazolymethane core as short as possible and hence our first approach employed the reaction of 2,2,2-tripyrazol-1-ylethoxide with polyfluoroalkylated triflate **2** (Scheme 1). However, at low temperatures no reaction occurred while under more forcing conditions a complex mixture was formed probably as a result of thiophilic attack of hard nucleophile on a sulfonyl group of the triflate [15].


We therefore turned our attention to Mitsunobu reaction as polyfluoroalkanols with short spacer between the hydroxy group

and the perfluorinated group are sufficiently acidic to undergo ether formation providing more efficient protocol using ADDP 1,1'-(azodicarbonyl)dipiperidine in combination with tributylphosphane is employed [16]. Indeed, model reaction of octan-1-ol (**4**) with 1,1,1,3,3,3-hexafluoropropan-2-ol (**5**, HFIP) gave the target product **7**, where a low yield of 28% was caused mainly by a small scale distillation. In contrast to that, only starting tripyrazolylethanol **1** was identified in the crude reaction mixture in an analogous reaction. Detailed ^{31}P NMR analysis of both reactions revealed primary formation of betain **3** formed from ADDP and Bu_3P resonating at +57.6 ppm. In the case of the former model reaction a signal at +97.8 ppm of intermediary alkoxyphosphonium **6** salt was observed after addition of fluoroalcohol **5**, while no such intermediate was detected in the latter reaction probably as a result of excessive steric hindrance around the reaction centre of the alcohol **1** (Scheme 2).


We finally turned our attention to the “conservative” strategy consisting of allylation, radical addition of perfluoroalkyl iodide and removal of the iodine atom. In contrast to the reaction with polyfluoroalkyl triflate **2**, substitution with allyl bromide (**8**) in analogy to Ref. [12] afforded excellent yield of the corresponding allyl ether **9**. Subsequent radical addition was performed with a series of perfluoroalkyl iodides **10** with the aim to observe how the length of the perfluorinated chain influences fluorophilicity pattern. Among various approaches, initiation with AIBN in the solvent-free system [17] used previously successfully by us [18] gave the best yields of the respective adducts **11** (Scheme 3, Table 1). Final removal of iodine atom with tributylstannane under radical condition following the conditions of Ref. [19] led to very good yields of the target ligands **12** after anhydrous work-up consisting of treatment with potassium fluoride [20] followed by filtration through a short silica plug (Scheme 3, Table 1).

2.2. Model complexations of ligand 12b

For comparison of complexing properties of the obtained polyfluoroalkylated ligands **12** with the parent tripyrazolymethane ligand, we synthesized model complexes **13–16** using Cu(II), Ni(II) and Co(II) nitrates, as well as Fe(II) tetrafluoroborate




Scheme 2.



Scheme 3.

Table 1
Yields of perfluoroalkylation/reduction of allyl ether **9**.

R_F	Compound	Yield (%)	Compound	Yield (%)
C ₄ F ₉	11a	51	12a	94
C ₆ F ₁₃	11b	72	12b	96
C ₈ F ₁₇	11c	84	12c	95
C ₁₁ F ₂₁	11d	58	12d	94
C ₁₂ F ₂₅	11e	60	12e	90





by stirring the ligand **12b** and the respective metal salt in a 2:1 ratio. In contrast to the original procedure for non-fluorinated tripyrazolymethane in which the complexation has been accomplished in water [21], we had to employ acetone as the solvent due to hydrophobic properties of ligands **12**. Complexes **13–16** were isolated in a quantitative yield by simple evaporation of the solvent and optional reprecipitation of their acetone solution with hexane (Scheme 4). Due to paramagnetic properties of complexes **13–15**, they were identified only by IR, MS and HRMS spectroscopy. Detailed analysis of isotopic patterns in zoom peaks of the MS spectra confirmed the presence of the respective cations by comparison with the simulated spectra. On the other hand, Fe complex **16** is diamagnetic and hence ¹H, ¹³C and ¹⁹F NMR spectra could be recorded with the complete characterization of the sandwich.

2.3. Fluorophilicity measurements

Fluorophilicities f_i were calculated as natural logarithms of fluorous partition coefficients $P_i(\text{FBS})$ between perfluoro(methylcyclohexane) and toluene obtained from gravimetric measurements according to our previous approach [22]. Due to a low content of fluorine all ligands **12** have fluorous partition coefficients lower than 1 and their fluorophilicity hence lies below zero. The highest value was achieved for ligand **12d**, i.e. $R_F = \text{C}_{10}\text{F}_{21}$, which is in agreement with previous experimental observations: for very long perfluorinated chains fluorophilicity sinks due to decreasing solubility in perfluorinated solvents [3a]. Surprisingly, charged complexes **13–16** have little higher $P_i(\text{FBS})$ and f_i values, again with very low solubility both in toluene and in perfluoromethylcyclohexane. The results of all fluorophilicity and solubility measurements are listed in Table 2.

Table 2
Fluorous partition coefficient and fluorophilicity values of ligands **12** and complexes **13–16** and solubilities of complexes **13–16**.

Compound	$P_i(\text{FBS})$	f_i	Compound	$P_i(\text{FBS})$	f_i	Solubility (mg/ml)	
						PFMC	Toluene
12a	0.04	−3.22	13	0.40	−0.92	1.4	3.6
12b	0.05	−3.00	14	0.25	−1.39	1.3	5.3
12c	0.07	−2.66	15	0.72	−0.33	1.0	1.4
12d	0.34	−1.08	16	0.23	−1.47	0.6	2.6
12e	0.24	−1.43					

**Fig. 1.** ORTEP [24] plot (50% probability) of ligand **12c**.**Fig. 2.** Crystal packing of ligand **12c**.

2.4. Crystal structure of ligand 12c

White crystals of sufficient quality for X-ray diffraction spectroscopy were obtained after several recrystallizations from chloroform. The crystal is highly disordered in the perfluoroalkyl part where two distinguished conformations could be recognized, probably due to loose packing of perfluorinated chains assembled into fluorous layers (Figs. 1 and 2) [23].

3. Conclusions

2,2,2-Tripyrazol-1-ylethanol was employed as the key intermediate for the synthesis of the first example of tripyrazolymethane ligands containing long polyfluoroalkylated chains. Although strategies employing either nucleophilic substitution of polyfluoroalkyl triflate with tripyrazolymethane-based alkoxide or Mitsunobu protocol with polyfluorinated alcohols were unsuccessful, allylation of the key intermediate followed by radical perfluoroalkylation/reduction sequence afforded a series of tripyrazolymethane ligands bearing polyfluoroalkoxyalkyl ponytail on the central methine carbon. Model complexations with Cu(II), Ni(II) and Co(II) nitrates yielded coloured paramagnetic sandwich complexes, the structure of which was confirmed by IR, MS and HRMS spectroscopy. In contrast to that, complexation with Fe(II) tetrafluoroborate led to diamagnetic complex which was identified by NMR spectroscopy. The ligands and their complexes displayed limited solubility in perfluorinated solvents and due to low fluorine content are not fluorophilic.

4. Experimental

4.1. General description of methods and materials

Temperature data were uncorrected. NMR spectra were recorded with a Varian MercuryPlus spectrometer, ¹H NMR spectra at 299.97 MHz and ¹³C NMR spectra at 75.43 MHz using residual deuterated solvent signals as the internal standards, ¹⁹F NMR spectra at 282.22 MHz using CCl₃F as the internal standard.

Chemical shifts are given in ppm, coupling constants in Hz. IR spectra were taken with a FTIR Nicolet 6700 instrument in CHCl_3 or KBr pellets. Mass spectra (ESI, APCI) were measured with a LCQ Fleet (Finnigan) instrument, HRMS spectra (ESI, APCI, FAB) with a LTQ Orbitrap XL (Thermo Fisher Scientific) or ZAB-EQ (VG Analytical) instruments.

All reactions were performed in dry inert atmosphere (Ar) in an oven-dried flask. 2,2,2-(Tripyrazol-1-yl)ethan-1-ol (**1**, Tpm CH_2OH) was prepared according to Ref. [14], (perfluorohexyl)methyl triflate (**2**) according to Ref. [8a]. Perfluoroalkyl iodides **11a–11e** were kindly gifted by Atochem. Perfluoro(methylcyclohexane) was purchased from Apollo Scientific, other reagents from Sigma–Aldrich. Dry DMF was obtained from Acros, toluene was dried over Na and distilled.

4.2. Attempted preparation of 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl 2,2,2-tripyrzazol-1-ylethyl ether based on polyfluoroalkylated triflate

A flask was charged with sodium hydride (73.7 mg, 1.02 mmol), tripyrazolyethanol **1** (250 mg, 1.02 mmol) and THF (20 mL), followed by addition of solution of 3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl triflate (**2**, 508 mg, 1.02 mmol) in THF (11 mL). The mixture was then refluxed for 5 h. Quenching the reaction with water, extraction with diethyl ether (3 \times 15 mL), drying the organic solution with sodium sulfate and evaporation of solvents on rotary vacuum evaporator gave unseparable mixture of products.

4.3. Model Mitsunobu preparation of 1,1,1,3,3,3-hexafluoropropan-2-yl octyl ether (7)

A flask was charged with octan-1-ol (**4**, 110 mg, 0.767 mmol), ADDP (1,1'-(azodicarbonyl)dipiperidine, 388 mg, 1.54 mmol), tributylphosphane (311 mg, 1.54 mmol) and toluene (11 mL). After 11 min, 1,1,1,3,3,3-hexafluoropropan-2-ol (**5**, 258 mg, 1.54 mmol) was added and the mixture was stirred overnight. White precipitate was filtered off and solvent was evaporated on rotary vacuum evaporator. Vacuum distillation (2.5 Pa) gave 60 mg (28%) of the target product **7**. ^1H NMR (299.97 MHz, CDCl_3): δ 0.89 (t, $^3J_{\text{H-H}} = 6.0$ Hz, 3H, CH_3), 1.20–1.45 (m, 12H, CCH_2C), 3.82 (t, $^3J_{\text{H-H}} = 6.5$ Hz, 2H, $\text{CH}_2\text{CH}_2\text{O}$), 4.00 (septet, $^3J_{\text{H-F}} = 6.2$ Hz, 1H, $\text{CH}(\text{CF}_3)_2$) ppm. ^{19}F NMR (282.23 MHz, CDCl_3): δ -74.7 (d, $^3J_{\text{H-F}} = 6$ Hz, 6F, $\text{CH}(\text{CF}_3)_2$) ppm. ^{13}C NMR (75.44 MHz, CDCl_3): δ 14.0 (CH_3), 22.6 (CH_2), 25.5 (CH_2), 29.2–29.4 (3C, CH_2), 31.8 ($\text{CH}_2\text{CH}_2\text{O}$), 75.7 (CH_2O), 76.4 (m, $\text{CH}(\text{CF}_3)_2$), 121.6 (q, $^1J_{\text{C-F}} = 284$ Hz) ppm. IR (ν/cm^{-1}): 2959 m, 2933 m, 2860 w, 1373 m, 1289 s, 1267 m, 1209 s, 1141 m, 1115 m. EA calcd. for $\text{C}_{11}\text{H}_{18}\text{F}_6\text{O}$ 48.96% C, 6.73% H, found 47.14% C, 6.47% H.

4.4. Attempted Mitsunobu preparation of hexafluoropropan-2-yl 2,2,2-tripyrzazol-1-ylethyl ether

A flask was charged with tripyrazolyethanol **1** (110 mg, 0.409 mmol), ADDP (206 mg, 0.819 mmol), toluene (11 mL) and tributylphosphane (166 mg, 0.819 mmol). After 11 min 1,1,1,3,3,3-hexafluoropropan-2-ol (**5**, 138 mg, 0.819 mmol) was added and the mixture was stirred overnight. White precipitate formed was filtered off and the solvent was removed on the rotary vacuum evaporator. By ^1H NMR analysis only starting tripyrazolyethanol **1** was detected in the reaction mixture.

4.5. Allyl 2,2,2-tripyrzazol-1-ylethyl ether (9)

A flask was charged with NaH (60 mg, 2.5 mmol), 2,2,2-(tripyrzazol-1-yl)ethan-1-ol (**1**, 500 mg, 2.05 mmol) and DMF (50 mL). Allyl bromide (**8**) was added and the mixture was stirred

at r.t. for 24 h. After addition of diethyl ether (20 mL), the mixture was extracted with water (3 \times 110 mL). The organic phase was dried with anh. Na_2SO_4 and solvents were removed on a rotary vacuum evaporator (50 $^\circ\text{C}/2$ h/2 kPa). Column chromatography (eluent: dichloromethane/ethyl acetate 3:1) of the residue gave ether **9** (0.53 g, 92%, light yellow viscous oil). ^1H NMR (299.97 MHz, CDCl_3): δ 3.97 (dt, $^3J_{\text{H-H}} = 9.0$ Hz, $^4J_{\text{H-H}} = 1.5$ Hz, 2H, $=\text{CHCH}_2$), 5.09 (s, 2H, OCH_2C); 5.17 (ddt, $^2J_{\text{H-H}} = 1.5$ Hz, $^3J_{\text{H-H}} = 9.5$ Hz, $^4J_{\text{H-H}} = 1.5$ Hz, 1H, *cis*- $\text{CH}_2=$), 5.21 (ddt, $^2J_{\text{H-H}} = 1.5$ Hz, $^3J_{\text{H-H}} = 16.6$ Hz, $^4J_{\text{H-H}} = 1.5$ Hz, 1H, *trans*- $\text{CH}_2=$), 5.78 (ddt, $^3J_{\text{H-H}} = 9.0$ Hz, $^3J_{\text{H-H}} = 9.5$ Hz, $^3J_{\text{H-H}} = 16.6$ Hz, 1H, $=\text{CHCH}_2$), 6.33 (dd, $^3J_{\text{H-H}} = 2.6$ Hz, $^3J_{\text{H-H}} = 1.8$ Hz, 3H, $\text{CHCH}=\text{CH}$), 7.42 (dd, $^3J_{\text{H-H}} = 2.6$ Hz, $^4J_{\text{H-H}} = 0.6$ Hz, 3H, $=\text{CHN}$), 7.65 (dd, $^3J_{\text{H-H}} = 1.8$ Hz, $^4J_{\text{H-H}} = 0.6$ Hz, 3H, $\text{CH}=\text{N}$) ppm. ^{13}C NMR (75.44 MHz, CDCl_3): δ 72.9 (OCH_2C), 73.1 ($\text{OCH}_2\text{CH}=\text{}$), 89.8 (CH_2C), 116.4 ($\text{CCH}=\text{C}$), 117.9 ($=\text{CH}_2$), 130.8 ($\text{CH}=\text{CH}_2$), 133.5 ($=\text{CHN}$), 141.3 ($\text{CH}=\text{N}$) ppm. IR (ν/cm^{-1}): 3130 w, 3116 w, 1515 m, 1423 m, 1387 s, 1322 s, 1200 s, 1163 s. MS (APCI), m/z (%): 285 [$\text{M}+\text{H}$] $^+$ (60), 213 [Pz_3C] $^+$ (110), 146 [Pz_2C] $^+$ (90). HRMS (ESI): [$\text{M}+\text{Na}$] $^+$ calcd. for $\text{C}_{14}\text{H}_{16}\text{N}_6\text{NaO}$ 307.1278, found 307.1273.

4.6. 2-Iodo-3-(perfluoroalkyl)propyl 2,2,2-tripyrzazol-1-ylethyl ether (11). General procedure

A flask was charged with allyl ether **9**, AIBN and perfluoroalkyl iodide **11**. A neat mixture was stirred for 3 h at 110 $^\circ\text{C}$. After cooling the mixture to r.t., product **11** was isolated by column chromatography.

4.7. 4,4,5,5,6,6,7,7,7-Nonafluoro-2-iodoheptyl 2,2,2-tripyrzazol-1-ylethyl ether (11a)

According to the general procedure, allyl ether **9** (250 mg, 0.88 mmol), perfluorobutyl iodide (**10a**, 465 mg, 1.32 mmol) and AIBN (5 mg, 0.026 mmol) yielded polyhalogenated ether **11a** (280 mg, 50.5%, m.p. 48.6–49.2 $^\circ\text{C}$, white crystals). ^1H NMR (299.97 MHz, CDCl_3): δ 2.59 (m, 2H, CH_2CF_2), 3.73 (m, 2H, CHICH_2), 4.23 (m, 1H, CHI), 5.19 (s, 2H, CH_2C), 6.35 (dd, $^3J_{\text{H-H}} = 2.6$ Hz, $^3J_{\text{H-H}} = 1.8$ Hz, 3H, $\text{CHCH}=\text{CH}$), 7.40 (dd, $^3J_{\text{H-H}} = 2.6$ Hz, $^4J_{\text{H-H}} = 0.6$ Hz, 3H, $=\text{CHN}$), 7.65 (dd, $^3J_{\text{H-H}} = 1.8$ Hz, $^4J_{\text{H-H}} = 0.6$ Hz, 3H, $\text{CH}=\text{N}$) ppm. ^{19}F NMR (282.23 MHz, CDCl_3): δ -81.4 (t, $^4J_{\text{F-F}} = 9$ Hz, 3F, CF_3), -113.4 (m, 2F, CH_2CF_2), -124.8 (m, 2F, CF_2), 126.3 (m, 2F, CF_3CF_2) ppm. ^{13}C NMR (75.44 MHz, CDCl_3): δ 13.2 (CHI), 37.2 (t, $^2J_{\text{C-F}} = 21$ Hz, CH_2CF_2), 74.0 (OCH_2C), 76.7 (OCH_2CHI), 89.5 (CH_2C), 116.7 ($\text{CHCH}=\text{CH}$), 112–120 (m, 4C, CF_2 and CF_3), 130.8 ($=\text{CHN}$), 141.5 ($\text{CH}=\text{N}$) ppm. IR (ν/cm^{-1}): 3123 w, 2940 w, 1516 m, 1426 m, 1228 s, 1132 s, 1117 s, 1188 s. MS (APCI), m/z (%): 630 [M] $^+$ (5), 594 [$\text{M-pz}+\text{MeOH}$] $^+$ (40), 563 [M-pz] $^+$ (30), 527 [$\text{MH-I}+\text{Na}$] $^+$ (90), 491 [$\text{MH-I-pz}+\text{MeOH}+\text{Na}$] $^+$ (110). HRMS (ESI): calcd. for $\text{C}_{18}\text{H}_{17}\text{F}_9\text{IN}_6\text{O}$ ([MH] $^+$) 631.0359, found 631.0358.

4.8. 4,4,5,5,6,6,7,7,8,8,9,9,9-Tridecafluoro-2-iodononyl 2,2,2-tripyrzazol-1-ylethyl ether (11b)

According to the general procedure, allyl ether **9** (250 mg, 0.88 mmol), perfluorohexyl iodide (**10b**, 588 mg, 1.32 mmol) and AIBN (5 mg, 0.026 mmol) yielded polyhalogenated ether **11b** (398 mg, 72.1%, m.p. 75.1–76.0 $^\circ\text{C}$, white crystals). ^1H NMR (299.97 MHz, acetone- d_6): δ 2.74 (m, 2H, CH_2CF_2), 3.89 (m, 2H, CHICH_2), 4.42 (m, 1H, CHI), 5.21 (s, 2H, CH_2C), 6.37 (dd, $^3J_{\text{H-H}} = 2.6$ Hz, $^3J_{\text{H-H}} = 1.8$ Hz, 3H, $\text{CHCH}=\text{CH}$), 7.50 (dd, $^3J_{\text{H-H}} = 2.6$ Hz, $^4J_{\text{H-H}} = 0.6$ Hz, 3H, $=\text{CHN}$), 7.62 (dd, $^3J_{\text{H-H}} = 1.8$ Hz, $^4J_{\text{H-H}} = 0.6$ Hz, 3H, $\text{CH}=\text{N}$) ppm. ^{19}F NMR (282.23 MHz, acetone- d_6): δ -80.6 (t, $^4J_{\text{F-F}} = 11$ Hz, 3F, CF_3), -113.2 (m, 2F, CH_2CF_2), -121.3 (m, 2F, CF_2), -122.3 (m, 2F, CF_2), -123.1 (m, 2F, CF_2), -125.7 (m, 2F, CF_3CF_2) ppm. ^{13}C NMR (75.44 MHz, acetone- d_6): δ 15.0 (CHI), 38.3 (t, $^2J_{\text{C-F}}$

$F = 21$ Hz, CH_2CF_2 , 75.1 (OCH₂C), 78.2 (OCH₂CHI), 90.6 (CH₂C), 117.7 (CHCH=CH), 111–128 (m, 6C, CF₂ and CF₃), 132.5 (=CHN), 142.4 (CH=N) ppm. IR (ν/cm^{-1}): 3123 w, 2941 w, 1516 m, 1425 m, 1235 s, 1140 s, 1188 s. MS (APCI), m/z (%): 730 [M]⁺ (20), 695 [M-pz+MeOH]⁺ (110), 664 [M-pz]⁺ (80), 627 [MH-I+Na]⁺ (60), 591 [MH-I-pz+MeOH+Na]⁺ (20). HRMS (ESI): calcd. for C₂₀H₁₆F₁₃IN₆-NaO ([M+Na]⁺) 753.0115, found 753.0098.

4.9. 4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-Heptadecafluoro-2-iodoundecyl 2,2,2-tripyrzazol-1-ylethyl ether (11c)

According to the general procedure, allyl ether **9** (250 mg, 0.88 mmol), perfluorooctyl iodide (**10c**, 720 mg, 1.32 mmol) and AIBN (5 mg, 0.026 mmol) yielded polyhalogenated ether **11c** (686 mg, 83.8%, m.p. 93.3–93.9 °C, white crystals). ¹H NMR (299.97 MHz, CDCl₃): δ 2.59 (m, 2H, CH₂CF₂), 3.76 (m, 2H, CHICH₂), 4.23 (m, 1H, CHI), 5.19 (s, 2H, CH₂C), 6.34 (dd, ³J_{H-H} = 2.6 Hz, ³J_{H-H} = 1.8 Hz, 3H, CHCH=CH), 7.40 (dd, ³J_{H-H} = 2.6 Hz, ⁴J_{H-H} = 0.6 Hz, 3H, =CHN), 7.65 (dd, ³J_{H-H} = 1.8 Hz, ⁴J_{H-H} = 0.6 Hz, 3H, CH=N) ppm. ¹⁹F NMR (282.23 MHz, CDCl₃): δ -81.1 (t, ⁴J_{F-F} = 11 Hz, 3F, CF₃), -114.3 (m, 2F, CH₂CF₂), -122.0 (m, 2F, CF₂), 122.4 (m, 4F, CF₂), -123.1 (m, 2F, CF₂), -124.0 (m, 2F, CF₂), -126.5 (m, 2F, CF₃CF₂) ppm. ¹³C NMR (75.44 MHz, CDCl₃): δ 13.3 (CHI), 37.4 (t, ²J_{C-F} = 17 Hz, CH₂CF₂), 74.0 (OCH₂C), 76.7 (OCH₂CHI), 89.5 (CH₂C), 116.7 (CHCH=CH), 118–124 (m, 8C, CF₂ and CF₃), 130.8 (=CHN), 141.5 (CH=N) ppm. IR (ν/cm^{-1}): 3124 w, 2923 w, 1516 m, 1426 m, 1244 s, 1202 s, 1146 s, 1117 s, 1141 s. MS (APCI), m/z (%): 830 [M]⁺ (5), 794 [M-pz+MeOH]⁺ (90), 763 [M-pz]⁺ (50), 727 [MH-I+Na]⁺ (110), 691 [MH-I-pz+MeOH+Na]⁺ (80). HRMS (ESI): calcd. for C₂₂H₁₇F₁₇IN₆O ([MH]⁺) 831.0232, found 831.0240.

4.10. 4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,13-Heneicosafuoro-2-iodotridecyl 2,2,2-tripyrzazol-1-ylethyl ether (11d)

According to the general procedure, allyl ether **9** (250 mg, 0.88 mmol), perfluorododecyl iodide (**10d**, 853 mg, 1.32 mmol) and AIBN (5 mg, 0.026 mmol) yielded polyhalogenated ether **11d** (475 mg, 58.1%, m.p. 114.1–114.8 °C, white crystals). ¹H NMR (299.97 MHz, CDCl₃): δ 2.58 (m, 2H, CH₂CF₂), 3.76 (m, 2H, CHICH₂), 4.23 (m, 1H, CHI), 5.20 (s, 2H, CH₂C), 6.34 (dd, ³J_{H-H} = 2.6 Hz, ³J_{H-H} = 1.8 Hz, 3H, CHCH=CH), 7.40 (dd, ³J_{H-H} = 2.6 Hz, ⁴J_{H-H} = 0.6 Hz, 3H, =CHN), 7.65 (dd, ³J_{H-H} = 1.8 Hz, ⁴J_{H-H} = 0.6 Hz, 3H, CH=N) ppm. ¹⁹F NMR (282.23 MHz, CDCl₃): δ -81.3 (t, ⁴J_{F-F} = 9 Hz, 3F, CF₃), -114.3 (m, 2F, CH₂CF₂), -122.3 (m, 11F, CF₂), -123.3 (m, 2F, CF₂), -124.0 (m, 2F, CF₂), -126.7 (m, 2F, CF₃CF₂) ppm. ¹³C NMR (75.44 MHz, CDCl₃): δ 15.6 (CHI), 37.5 (t, ²J_{C-F} = 18 Hz, CH₂CF₂), 74.0 (OCH₂C), 76.7 (OCH₂CHI), 89.3 (CH₂C), 116.6 (CHCH=CH), 117–126 (m, 10C, CF₂ and CF₃), 130.9 (=CHN), 141.4 (CH=N) ppm. IR (ν/cm^{-1}): 3123 w, 2941 w, 1424 m, 1245 m, 1209 s, 1150 s, 1141 m. MS (APCI), m/z (%): 930 [M]⁺ (20), 894 [M-pz+MeOH]⁺ (40), 827 [MH-I+Na]⁺ (30), 791 [MH-I-pz+MeOH+Na]⁺. HRMS (ESI): calcd. for C₂₄H₁₆F₂₁IN₆NaO ([M+Na]⁺) 952.9987, found 952.9982.

4.11. 4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15,15-Pentacosafuoro-2-iodopentadecyl 2,2,2-tripyrzazol-1-ylethyl ether (11e)

According to the general procedure, allyl ether **9** (250 mg, 0.88 mmol), perfluorododecyl iodide (**10e**, 953 mg, 1.32 mmol) and AIBN (5 mg, 0.026 mmol) yielded polyhalogenated ether **11e** (544 mg, 60.1%, m.p. 130.5–131.0 °C, white crystals). ¹H NMR (299.97 MHz, CDCl₃): δ 2.56 (m, 2H, CH₂CF₂), 3.76 (m, 2H, CHICH₂), 4.23 (m, 1H, CHI), 5.19 (s, 2H, CH₂C), 6.35 (dd, ³J_{H-H} = 2.6 Hz, ³J_{H-H} = 1.8 Hz, 3H, CHCH=CH), 7.40 (dd, ³J_{H-H} = 2.6 Hz, ⁴J_{H-H} = 0.6 Hz, 3H, =CHN), 7.65 (dd, ³J_{H-H} = 1.8 Hz, ⁴J_{H-H} = 0.6 Hz, 3H, CH=N) ppm. ¹⁹F NMR (282.23 MHz, CDCl₃): δ -81.2 (t, ⁴J_{F-F} = 11 Hz, 3F,

CF₃), -114.3 (m, 2F, CH₂CF₂), -122.2 (m, 12F, CF₂), -123.2 (m, 2F, CF₂), -124.0 (m, 2F, CF₂), -126.6 (m, 2F, CF₃CF₂) ppm. ¹³C NMR (75.44 MHz, CDCl₃): δ 14.6 (CHI), 38.7 (t, ²J_{C-F} = 19 Hz, CH₂CF₂), 74.0 (OCH₂C), 76.7 (OCH₂CHI), 89.6 (CH₂C), 116.7 (CHCH=CH), 118–126 (m, 12C, CF₂ and CF₃), 130.8 (=CHN), 141.6 (CH=N) ppm. IR (ν/cm^{-1}): 3120 w, 2942 w, 1516 m, 1425 m, 1241 m, 1147 s, 1111 m, 1141 m. MS (APCI), m/z (%): 1130 [M]⁺ (11), 994 [M-pz+MeOH]⁺ (40), 927 [MH-I+Na]⁺ (60), 891 [MH-I-pz+MeOH+Na]⁺ (110). HRMS (ESI): calcd. for C₂₆H₁₇F₂₅IN₆O ([MH]⁺) 1131.0114, found 1131.0115.

4.12. 3-(Perfluoroalkyl)propyl 2,2,2-tripyrzazol-1-ylethyl ether (12). General procedure

A flask was charged with polyhalogenated ether **11**, AIBN and toluene, followed by Bu₃SnH. The mixture was heated to 75 °C for 1 h. After cooling to r.t., KF was added and the precipitate formed was separated by filtration. Toluene was removed on a rotary vacuum evaporator (60 °C/2 h/2 kPa). Column chromatography (eluent: dichloromethane/ethyl acetate 6:1) of the residue gave the target ligand **12**.

4.13. 4,4,5,5,6,6,7,7,7-Nonafluoroheptyl 2,2,2-tripyrzazol-1-ylethyl ether (12a)

According to the general procedure, polyhalogenated ether **11a** (100 mg, 0.158 mmol), Bu₃SnH (92 mg, 0.32 mmol) and AIBN (2 mg, 0.016 mmol) in toluene (3 mL) yielded after treatment with KF (18 mg, 0.32 mmol) polyfluorinated ether **12a** (75 mg, 94%, m.p. 76.7–77.4 °C, white crystals). ¹H NMR (299.97 MHz, CDCl₃): δ 1.80 (m, 4H, CF₂CH₂ and CF₂CH₂CH₂), 3.57 (t, ³J_{H-H} = 5.6 Hz, 2H, CH₂CH₂O), 5.09 (s, 2H, CH₂C), 6.33 (dd, ³J_{H-H} = 2.6 Hz, ³J_{H-H} = 1.8 Hz, 3H, CHCH=CH), 7.37 (dd, ³J_{H-H} = 2.6 Hz, ⁴J_{H-H} = 0.6 Hz, 3H, =CHN), 7.64 (dd, ³J_{H-H} = 1.8 Hz, ⁴J_{H-H} = 0.6 Hz, 3H, CH=N) ppm. ¹⁹F NMR (282.23 MHz, CDCl₃): δ -81.6 (t, ⁴J_{F-F} = 9 Hz, 3F, CF₃), -115.3 (m, 2F, CH₂CF₂), -125.0 (m, 2F, CF₂), 126.6 (m, 2F, CF₃CF₂) ppm. ¹³C NMR (75.44 MHz, CDCl₃): δ 20.5 (CH₂CH₂CH₂), 27.4 (t, ²J_{C-F} = 23 Hz, CF₂CH₂), 70.7 (OCH₂C), 74.0 (OCH₂CH₂), 89.7 (CH₂C), 116.5 (CHCH=CH), 113–122 (m, 4C, CF₂ and CF₃), 130.7 (=CHN), 141.3 (CH=N) ppm. IR (ν/cm^{-1}): 3138 w, 2945 w, 1518 m, 1426 m, 1230 s, 1129 s, 1163 m. MS (APCI), m/z (%): 505 [M]⁺ (5), 469 [M-pz+MeOH]⁺ (110), 438 [M-pz]⁺ (50). HRMS (ESI): calcd. for C₁₈H₁₇F₉N₆NaO ([M+Na]⁺) 527.1212, found 527.1208.

4.14. 4,4,5,5,6,6,7,7,8,8,9,9,9-Tridecafluorononyl 2,2,2-tripyrzazol-1-ylethyl ether (12b)

According to the general procedure, polyhalogenated ether **11b** (100 mg, 0.137 mmol), Bu₃SnH (80 mg, 0.27 mmol) and AIBN (2 mg, 0.016 mmol) in toluene (3 mL) yielded after treatment with KF (16 mg, 0.27 mmol) polyfluorinated ether **12b** (79 mg, 96%, m.p. 80.9–81.7 °C, white crystals). ¹H NMR (299.97 MHz, CDCl₃): δ 1.80 (m, 4H, CF₂CH₂ and CF₂CH₂CH₂), 3.58 (t, ³J_{H-H} = 5.6 Hz, 2H, CH₂CH₂O), 5.09 (s, 2H, CH₂C), 6.33 (dd, ³J_{H-H} = 2.6 Hz, ³J_{H-H} = 1.8 Hz, 3H, CHCH=CH), 7.37 (dd, ³J_{H-H} = 2.6 Hz, ⁴J_{H-H} = 0.6 Hz, 3H, =CHN), 7.65 (dd, ³J_{H-H} = 1.8 Hz, ⁴J_{H-H} = 0.6 Hz, 3H, CH=N) ppm. ¹⁹F NMR (282.23 MHz, CDCl₃): δ -81.3 (t, ⁴J_{F-F} = 11 Hz, 3F, CF₃), -115.1 (m, 2F, CF₂), -122.5 (m, 2F, CF₂), -123.5 (m, 2F, CF₂), -124.1 (m, 2F, CF₂), -126.7 (m, 2F, CF₃CF₂) ppm. ¹³C NMR (75.44 MHz, CDCl₃): δ 20.5 (CH₂CH₂CH₂), 27.5 (t, ²J_{C-F} = 23 Hz, CF₂CH₂), 70.7 (OCH₂C), 74.0 (OCH₂CH₂), 89.7 (CH₂C), 116.5 (CHCH=CH), 111–125 (m, 6C, CF₂ and CF₃), 130.7 (=CHN), 141.4 (CH=N) ppm. IR (ν/cm^{-1}): 3145 w, 2942 w, 1518 m, 1425 m, 1225 s, 1141 s, 1161 m. MS (APCI), m/z (%): 604 [M]⁺ (11), 568 [M-pz+MeOH]⁺ (110), 537 [M-pz]⁺ (80). HRMS

(ESI): calcd. for $C_{20}H_{18}F_{13}N_6O$ ($[MH]^+$) 605.1329, found 605.1328.

4.15. 4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-Heptadecafluoroundecyl 2,2,2-tripyrzazol-1-ylethyl ether (**12c**)

According to the general procedure, polyhalogenated ether **11c** (100 mg, 0.121 mmol), Bu_3SnH (71 mg, 0.24 mmol) and AIBN (2 mg, 0.016 mmol) in toluene (3 mL) yielded after treatment with KF (14 mg, 0.24 mmol) polyfluorinated ether **12c** (81 mg, 95%, m.p. 90.4–91.0 °C, white crystals). 1H NMR (299.97 MHz, $CDCl_3$): δ 1.81 (m, 4H, CF_2CH_2 and $CF_2CH_2CH_2$), 3.57 (t, $^3J_{H-H} = 5.0$ Hz, 2H, CH_2CH_2O), 5.11 (s, 2H, CH_2C), 6.33 (dd, $^3J_{H-H} = 2.6$ Hz, $^3J_{H-H} = 1.8$ Hz, 3H, $CHCH=CH$), 7.38 (dd, $^3J_{H-H} = 2.6$ Hz, $^4J_{H-H} = 0.6$ Hz, 3H, $=CHN$), 7.66 (dd, $^3J_{H-H} = 1.8$ Hz, $^4J_{H-H} = 0.6$ Hz, 3H, $CH=N$) ppm. ^{19}F NMR (282.23 MHz, $CDCl_3$): δ -81.3 (t, $^4J_{F-F} = 11$ Hz, 3F, CF_3), -115.1 (bs, 2F, CH_2CF_2), -122.5 (bs, 6F, CF_2), 123.3 (bs, 2F, CF_2), -124.1 (bs, 2F, CF_2), -126.7 (bs, 2F, CF_3CF_2) ppm. ^{13}C NMR ($CDCl_3$): δ 20.4 ($CH_2CH_2CH_2$), 27.5 (t, $^2J_{C-F} = 23$ Hz, CF_2CH_2), 70.7 (OCH_2C), 74.0 (OCH_2CH_2), 89.7 (CH_2C), 116.5 ($CHCH=CH$), 118–125 (m, 8C, CF_2 and CF_3), 130.7 ($=CHN$), 141.4 ($=CHN$) ppm. IR (ν/cm^{-1}): 3159 w, 3144 w, 2960 w, 2888 w, 1518 m, 1426 m, 1386 m, 1330 s, 1287 s, 1251 s, 1209 s, 1155 s, 1111 s, 1161 s, 1119 m, 917 m, 865 m, 786 s, 769 s, 758 s, 658 m. MS (APCI): 704 $[M]^+$ (50), 637 $[M-pz]^+$ (60), 601 (110), 565 (50). NaHRMS (ESI): calcd. for $C_{22}H_{17}F_{17}N_6NaO$ ($[M+Na]^+$) 727.1185, found 727.1179.

4.16. 4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,13-Heneicosafuorotridecyl 2,2,2-tripyrzazol-1-ylethyl ether (**12d**)

According to the general procedure, polyhalogenated ether **11d** (100 mg, 0.117 mmol), Bu_3SnH (69 mg, 0.21 mmol) and AIBN (2 mg, 0.016 mmol) in toluene (3 mL) yielded after treatment with KF (12 mg, 0.21 mmol) polyfluorinated ether **12d** (81 mg, 94%, m.p. 115.6–116.4 °C, white crystals). 1H NMR (299.97 MHz, $CDCl_3$): δ 1.77 (m, 4H, CF_2CH_2 and $CF_2CH_2CH_2$), 3.57 (t, $^3J_{H-H} = 5.4$ Hz, 2H, CH_2CH_2O), 5.09 (s, 2H, CH_2C), 6.33 (dd, $^3J_{H-H} = 2.6$ Hz, $^3J_{H-H} = 1.8$ Hz, 3H, $CHCH=CH$), 7.37 (dd, $^3J_{H-H} = 2.6$ Hz, $^4J_{H-H} = 0.6$ Hz, 3H, $=CHN$), 7.65 (dd, $^3J_{H-H} = 1.8$ Hz, $^4J_{H-H} = 0.6$ Hz, 3H, $CH=N$) ppm. ^{19}F NMR (282.23 MHz, $CDCl_3$): δ -81.2 (t, $^4J_{F-F} = 9$ Hz, 3F, CF_3), -115.0 (m, 2F, CF_2), -122.2 (m, 11F, CF_2), -123.1 (m, 2F, CF_2), -124.0 (m, 2F, CF_2), 126.5 (m, 2F, CF_2) ppm. ^{13}C NMR (75.44 MHz, $CDCl_3$): δ 20.5 ($CH_2CH_2CH_2$), 27.5 (t, $^2J_{C-F} = 23$ Hz, CF_2CH_2), 70.7 (OCH_2C), 74.0 (OCH_2CH_2), 89.7 (CH_2C), 116.5 ($CHCH=CH$), 118–125 (m, 10C, CF_2 and CF_3), 130.7 ($=CHN$), 141.4 ($CH=N$) ppm. IR (ν/cm^{-1}): 3143 w, 2942 w, 2886 w, 1517 m, 1425 m, 1390 m, 1325 m, 1248 m, 1206 s, 1155 s, 1159 m, 1141 m, 1118 m, 948 m, 913 m, 864 m, 754 m. MS (APCI), m/z (%): 804 $[M]^+$ (50), 768 $[Mpz+MeOH]^+$ (90), 737 $[M-pz]^+$ (110). HRMS (ESI): calcd. for $C_{24}H_{18}F_{21}N_6ONa$ ($[M+Na]^+$) 827.1121, found 827.1115.

4.17. 4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,12,12,13,13,14,14,15,15,15-Pentacosafuoropentadecyl 2,2,2-tripyrzazol-1-ylethyl ether (**12e**)

According to the general procedure, polyhalogenated ether **11e** (100 mg, 0.097 mmol), Bu_3SnH (58 mg, 0.19 mmol) and AIBN (2 mg, 0.016 mmol) in toluene (3 mL) yielded after treatment with KF (12 mg, 0.21 mmol) polyfluorinated ether **12e** (79 mg, 90%, m.p. 121.9–122.5 °C, white crystals). 1H NMR (299.97 MHz, $CDCl_3$): δ 1.81 (m, 4H, CF_2CH_2 and $CF_2CH_2CH_2$), 3.58 (t, $^3J_{H-H} = 5.5$ Hz, 2H, CH_2CH_2O), 5.11 (s, 2H, CH_2C), 6.33 (dd, 3H, $^3J_{H-H} = 2.6$ Hz, $^3J_{H-H} = 1.8$ Hz, 3H, $CHCH=CH$), 7.37 (dd, $^3J_{H-H} = 2.6$ Hz, $^4J_{H-H} = 0.6$ Hz, 3H, $=CHN$), 7.65 (dd, $^3J_{H-H} = 1.8$ Hz, $^4J_{H-H} = 0.6$ Hz, 3H, $CH=N$) ppm. ^{19}F NMR (282.23 MHz, $CDCl_3$): δ -81.2 (t, $^4J_{F-F} = 9$ Hz, 3F, CF_3), -113.3 (m, 2F, CF_2), -122.2 (m, 12F, CF_2), -123.2 (m, 2F, CF_2),

124.1 (m, 2F, CF_2), -126.6 (m, 2F, CF_2) ppm. ^{13}C NMR (75.44 MHz, $CDCl_3$): δ 20.5 ($CH_2CH_2CH_2$), 27.5 (t, $^2J_{C-F} = 23$ Hz, CF_2CH_2), 70.7 (OCH_2C), 74.0 (OCH_2CH_2), 89.7 (CH_2C), 116.5 ($CHCH=CH$), 118–126 (m, 4C, CF_2 a CF_3), 130.7 ($=CHN$), 141.4 ($CH=N$) ppm. IR (ν/cm^{-1}): 3158 w, 2943 w, 2888 w, 1517 m, 1425 m, 1389 m, 1320 m, 1284 m, 1199 s, 1153 s, 1196 m, 1162 m, 1117 m, 948 m, 914 m, 863 m, 753 m. MS (APCI), m/z (%): 904 $[M]^+$ (50), 837 $[M-pz]^+$ (110). HRMS (ESI): calcd. for $C_{24}H_{18}F_{21}N_6ONa$ ($[M+Na]^+$) 927.0957, found 927.0955.

4.18. Preparation of complexes of tripyrazolymethane **12b**. General procedure

A flask was charged with tripyrazolymethane **12b**, metal nitrate and acetone. The mixture was stirred at r.t. overnight and the solvent was removed on the rotary vacuum evaporator (40 °C, 0.5 h, 11 kPa).

4.19. Bis(η^3 -(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluorononyl) (2,2,2-tripyrzazol-1-ylethyl- κ^3N,N,N') ether)copper(II) nitrate (**13**)

According to the general procedure, polyhalogenated ether **12b** (100 mg, 0.165 mmol) and $Cu(NO_3)_2 \cdot 3H_2O$ (17 mg, 0.069 mmol) in acetone (11 mL) gave quantitative yield of polyfluorinated complex **13** (115 mg, 99.6%, blue crystals). IR (ν/cm^{-1}): 3135 w, 2952 w, 2890 w, 1519 m, 1484 m, 1413 m, 1390 m, 1337 s, 1237 s, 1204 s, 1145 s, 1111 m, 1127 m, 856 w, 761 m. MS (ESI), m/z (%): 1332 $[MNO_3]^-$ (110), 729 $[M-tpm^F-NO_3]^-$ (110), 636 $[M-2NO_3]^{2+}$ (40).

4.20. Bis(η^3 -(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluorononyl) (2,2,2-tripyrzazol-1-ylethyl- κ^3N,N,N') ether)nickel(II) nitrate (**14**)

According to the General procedure, polyhalogenated ether **12b** (100 mg, 0.165 mmol) and $Ni(NO_3)_2 \cdot 3H_2O$ (20 mg, 0.069 mmol) in acetone (11 mL) gave quantitative yield of polyfluorinated complex **14** (115 mg, 99.9%, light violet crystals). IR (ν/cm^{-1}): 3132 w, 2950 w, 2895 w, 1519 m, 1413 m, 1360 m, 1319 s, 1224 s, 1188 s, 1140 s, 1116 m, 1178 m, 1124 m, 975 m, 851 m, 756 m. MS (ESI), m/z (%): 1328 $[M-NO_3]^-$ (40), 725 $[M-tpm^F-NO_3]^-$ (110), 633 $[M-2NO_3]^{2+}$ (11). HRMS (ESI): calcd. for $C_{40}H_{34}F_{26}N_{12}NiO_2/2$ ($[M-2NO_3]^{2+}$) 633.0933, found 633.0930.

4.21. Bis(η^3 -(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluorononyl) (2,2,2-tripyrzazol-1-ylethyl- κ^3N,N,N') ether)cobalt(II) nitrate (**15**)

According to the general procedure, polyhalogenated ether **12b** (100 mg, 0.165 mmol) and $Co(NO_3)_2 \cdot 6H_2O$ (20 mg, 0.069 mmol) in acetone (11 mL) gave quantitative yield of polyfluorinated complex **15** (115 mg, 99.8%, yellow crystals). IR (ν/cm^{-1}): 3136 w, 2950 w, 2893 w, 1519 m, 1413 m, 1387 m, 1343 s, 1250 s, 1211 s, 1147 m, 1111 m, 1129 m, 853 m, 757 m. MS (ESI), m/z (%): 1329 $[M-NO_3]^-$ (110), 725 $[M-tpm^F-NO_3]^-$ (50), 634 $[M-2NO_3]^{2+}$ (40).

4.22. Bis(η^3 -(4,4,5,5,6,6,7,7,8,8,9,9,9-tridecafluorononyl) (2,2,2-tripyrzazol-1-ylethyl- κ^3N,N,N') ether)iron(II) tetrafluoroborate (**16**)

According to the general procedure, polyhalogenated ether **12b** (100 mg, 0.165 mmol) and $Fe(BF_4)_2 \cdot 6H_2O$ (28 mg, 0.083 mmol) in methanol (5 mL) gave quantitative yield of polyfluorinated complex **16** (111 mg, 99.6%, dark pink crystals). 1H NMR (299.97 MHz, CD_3CN): δ 2.34 (m, 8H, CF_2CH_2 and $CF_2CH_2CH_2$), 4.22 (bs, 4H, CH_2CH_2O), 5.62 (bs, 4H, CH_2C), 6.58 (bs, 6H, $CHCH=CH$), 7.30 (bs, 6H, $=CHN$), 8.51 (bs, 6H, $CH=N$) ppm. ^{19}F NMR (282.23 MHz, CD_3CN): δ -80.6 (m, 6F, CF_3), -113.6 (m, 4F,

CF₂CH₂), –121.3 (m, 4F, CF₂), –122.3 (m, 4F, CF₂), –122.9 (m, 4F, CF₂), –125.7 (m, 4F, CF₂), –149.8 (m, 4F, BF₄) ppm. ¹³C NMR (75.44 MHz, CD₃CN): δ 21.8 (CH₂CH₂CH₂), 28.7 (t, ²J_{C-F} = 23 Hz, CF₂CH₂), 68.3 (OCH₂C), 71.9 (OCH₂CH₂), 84.6 (CH₂C), 110.6 (CHCH=CH), 111–125 (m, 6C, CF₂ and CF₃), 138.1 (=CHN), 151.1 (CH=N) ppm. MS (ESI), *m/z* (%): 632 [M–2BF₄]²⁺ (100). HRMS (ESI): calcd. for C₄₀H₃₄F₂₆N₁₂O₂Fe/2 ([M–2BF₄]²⁺) 632.09255, found 632.09266.

4.23. Example of partition coefficient and fluorophilicity measurement: ligand **12d**

The vial was charged with polyfluoroalkylated tripyrazolylmethane **12d**, toluene (1 mL) and perfluoro(methylcyclohexane) (1 mL). The mixture was stirred for 2 h while thermostatted to 25 °C (298 K) and left to stand for 2 h. 0.5 mL of each layer was removed and evaporated on rotary vacuum evaporator (25 °C, 1 h, 11 kPa). Both residues were carefully weighted yielding 0.86 mg of compound **12d** in the fluororous and 2.55 mg of compound **12d** in the toluene layer, which corresponds to *P*_f(FBS) = 0.34 and fluorophilicity value *f*_i = –1.1.

Acknowledgements

We thank the Ministry of Education, Youth and Sports of the Czech Republic (Project KONTAKT ME09114–ME857, Research Centre LC 06070, Research Projects Nos. 6046137301, 6046137302 and NPVII 2B08021) for financial support.

References

- [1] (a) J.A. Gladysz, D.P. Curran, I.T. Horváth (Eds.), *Handbook of Fluororous Chemistry*, Wiley-VCH, Weinberg, 2004; (b) J.A. Gladysz, in: P.T. Anastas, R.H. Crabtree (Eds.), *Handbook of Green Chemistry: Green Catalysis*, Wiley-VCH, Weinberg, 2004, pp. 17–38; (c) W. Zhang, *Green Chem.* 11 (2009) 911–920.
- [2] (a) L.J. Alvey, D. Rutherford, J.J.J. Juliette, J. Gladysz, *J. Org. Chem.* 63 (1998) 6302–6308; (b) P. Bhattacharyya, D. Gudmunsen, E.G. Hope, R.D.W. Kemmitt, D.R. Paige, A.M. Stuart, *J. Chem. Soc. Perkin Trans. 1* (1997) 3609–3612; (c) S. Kainz, Z. Luo, D.P. Curran, W. Leitner, *Synthesis* (1998) 1425–1427; (d) B. Richter, A.L. Spek, G. van Koten, B.-J. Deelman, *J. Am. Chem. Soc.* 122 (2000) 3945–3951; (e) M. Wende, F. Seidel, J.A. Gladysz, *J. Fluorine Chem.* 124 (2003) 45–54; (f) J. Bayardon, M. Cavazzini, D. Maillard, G. Pozzi, S. Quici, D. Sinou, *Tetrahedron: Asymmetry* 14 (2003) 2215–2224.
- [3] (a) R.P. Hughes, H.A. Trujillo, *Organometallics* 15 (1996) 286–294; (b) R.P. Hughes, T.L. Husebo, A.L. Rheingold, L.M. Liable-Sands, G.P.A. Yap, *Organometallics* 16 (1997) 5–7; (c) R.P. Hughes, S.M. Maddock, I.A. Guzei, L.M. Liable-Sands, A.L. Rheingold, *J. Am. Chem. Soc.* 123 (2001) 3279–3288; (d) J. Čermák, K. Auerová, H.T.T. Nguyen, V. Blechta, P. Vojtíšek, J. Kvičala, *Collect. Czech. Chem. Commun.* 66 (2001) 382–396; (e) J. Čermák, J. Žádný, A. Krupková, K. Lopatová, A. Vlachová, T.H.N. Thi, J. Šauliová, J. Sýkora, I. Čiřarová, *J. Organomet. Chem.* 692 (2007) 1557–1570; (f) J. Čermák, A. Krupková, K. Auerová, M. Zamrza, T.H.N. Thi, P. Vojtíšek, I. Čiřarová, *J. Organomet. Chem.* 695 (2011) 375.
- [4] E.G. Sokolova, G.P. Chalykh, T.A. Malikova, L.B. Sevost'yanova, O.A. Nemchinova, *Zh. Obshch. Khim.* 43 (1973) 1333.
- [5] (a) V. Herrera, P.J.F. De Rege, I.T. Horváth, T. Le Husebo, R.P. Hughes, *Inorg. Chem. Commun.* 1 (1998) 197–199; (b) S.R. Wilson, M.E. Yurchenko, D.I. Schuster, *J. Org. Chem.* 65 (2000) 2619.
- [6] D. Hazáfy, M. Sobocíková, P. Štěpnička, J. Ludvík, M. Kotora, *J. Fluorine Chem.* 124 (2003) 177–181.
- [7] (a) J. Čermák, L. Šťastná, J. Sýkora, I. Čiřarová, J. Kvičala, *Organometallics* 23 (2004) 2850–2854; (b) P.G. Merle, V. Cheron, H. Hagen, M. Lutz, A.L. Spek, B.-J. Deelman, G. van Koten, *Organometallics* 24 (2005) 1620–1630; (c) L. Červenková-Šťastná, K. Auerová, J. Kvičala, J. Čermák, *J. Organomet. Chem.* 692 (2007) 1974–1982; (d) L. Červenková-Šťastná, J. Čermák, P. Cuřínová, J. Sýkora, *J. Organomet. Chem.* 695 (2011) 537–545; (e) G.S. Smith, S.K. Patra, L. Vanderark, S. Saithong, J.P.H. Charmant, I. Manners, *Macromol. Chem. Phys.* 211 (2011) 303–312; (f) J. Campora, I. Matas, P. Palma, E. Alvarez, H. Kleijn, B.-J. Deelman, E. Passaglia, *J. Organomet. Chem.* 695 (2011) 1794–1800.
- [8] (a) T. Bříza, J. Kvičala, P. Mysík, O. Paleta, J. Čermák, *Synlett* (2001) 685–687; (b) T. Bříza, J. Kvičala, O. Paleta, J. Čermák, *Tetrahedron* 58 (2002) 3841–3846; (c) J. Kvičala, T. Bříza, O. Paleta, K. Auerová, J. Čermák, *Tetrahedron* 58 (2002) 3847–3854; (d) L.V. Dinh, J.A. Gladysz, *Chem. Commun.* (2004) 998–999; (e) L.V. Dinh, J.A. Gladysz, *Chem. Eur. J.* 11 (2005) 7211–7222; (f) T. Bříza, M. Havlík, D. Hazáfy, J. Čermák, M. Kotora, J. Kvičala, Unpublished results.
- [9] (a) S. Trofimenko, *Chem. Rev.* 93 (1993) 943–980; (b) F.T. Edelmann, *Angew. Chem. Int. Ed.* 40 (2001) 1656–1660; (c) C. Pettinari, C. Santini, *Compr. Coord. Chem. II* 1 (2004) 159–211; (d) S. Trofimenko, *Polyhedron* 23 (2004) 197–203.
- [10] (a) A. Włodarczyk, R.M. Richardson, M.D. Ward, J.A. McCleverty, M.H.B. Hursthouse, S.J. Coles, *Polyhedron* 15 (1996) 27–35; (b) S.L. Guo, F. Peters, F. Fabrizi de Biani, J.W. Bats, E. Herdtweck, P. Zanello, M. Wagner, *Inorg. Chem.* 40 (2001) 4928–4936; (c) A.L. Rheingold, L.M. Liable-Sands, J.A. Golan, S. Trofimenko, *Eur. J. Inorg. Chem.* (2003) 2767–2773; (d) G.H. Maunder, M.R. Russo, A. Sella, *Polyhedron* 23 (2004) 2709–2714; (e) D.L. Reger, M.E. Tarquini, *Inorg. Chem.* 21 (1982) 840–842; (f) D.L. White, J.W. Faller, *J. Am. Chem. Soc.* 114 (1982) 1548–1552.
- [11] (a) H.R. Bigmore, S.C. Lawrence, P. Mountford, C.S. Tredget, *Dalton Trans.* (2005) 635–651; (b) C. Pettinari, R. Pettinari, *Coord. Chem. Rev.* 249 (2005) 525–543.
- [12] D.L. Reger, T.C. Grattan, *Synthesis* (2003) 350–356.
- [13] A. Sánchez-Méndez, G.F. Silvestri, E. de Jesús, F.J. de la Mata, J.C. Flores, R. Gómez, P. Gómez-Sal, *Eur. J. Inorg. Chem.* (2004) 3287–3296.
- [14] D.L. Reger, *J. Organomet. Chem.* 607 (2000) 120–128.
- [15] P. Johncock, *J. Fluorine Chem.* 4 (1974) 25–33.
- [16] J.R. Falck, J. Yu, H.-S. Cho, *Tetrahedron Lett.* 35 (1994) 5997–6000.
- [17] B. Boutevin, F.G. Pietrasanta, A. Ratsimihety, G. Caporiccio, *J. Fluorine Chem.* 70 (1995) 53–57.
- [18] J. Kvičala, T. Bříza, O. Paleta, J. Čermák, *Collect. Czech. Chem. Commun.* 67 (2002) 1345–1358.
- [19] G. Merhi, A.W. Coleman, J.-P. Devissaguet, G.M. Barratt, *J. Med. Chem.* 39 (1996) 4483–4488.
- [20] G.S. Bates, M.D. Fryzuk, C. Stone, *Can. J. Chem.* 65 (1987) 2612–2617.
- [21] S. Trofimenko, *J. Am. Chem. Soc.* 92 (1970) 5118–5126.
- [22] (a) O. Kysilka, M. Rybáčková, M. Skalický, M. Kvičalová, J. Cvačka, J. Kvičala, *J. Fluorine Chem.* 130 (2009) 629–639; (b) M. Skalický, M. Rybáčková, O. Kysilka, M. Kvičalová, J. Cvačka, J. Kvičala, *J. Fluorine Chem.* 130 (2009) 966–973.
- [23] Crystallographic data for the structural analysis has been deposited with the Cambridge Crystallographic Data Centre, CCDC No. 805984 for compound **12c**. Copies of this information may be obtained free of charge from The Director, CCDC, 12 Union Road, Cambridge, CB2 1EZ, UK (fax: +44 1223 336 033; e mail: deposit@ccdc.cam.ac.uk, or www: http: www.ccdc.cam.ac.uk).
- [24] L.J. Farrugia, *J. Appl. Crystallogr.* 30 (1997) 565.